title: [Metoclopramide test in the patients with hyperprolactinemia due to end-stage renal failure].
abstract: Evaluation of metoclopramide (MTC) test values in end-stage renal disease patients undergoing hemodialysis with different level of hyperprolactinemia was aim of the study. Clinical value of application of the MTC test and influence of different laboratory and clinical factors including erytropoietin treatment were examined. Sixty-eight hemodialysed patients (31 male and 37 female) aged 20-74 yr. (medium 48 +/- 13 yr.) underwent the MTC test, the control group consisted of 8 healthy volunteers (4 male and 4 female). 10mg of MTC was given i.v. and serum level of PRL was determined in 0, 30 and 60 min. after injection. Significant suppression of PRL stimulation in the patients was shown as compared with the controls after 30 min and delayed decrease of the curve values was found. An increase in the PRL level after 60 min in investigated group was lower than in control. Lower relative enhance of PRL level in 30 min was found and slower decrease after 60 min. Despite the slower decrease PRL level was lower in the patients than in the controls after 60 min. The highest relative increase in PRL level after 30 min was observed in the patients with lowest initial level of PRL (r=-0.471; p<0.001). Erytropoietin administration improved the response in the test (p=0.005) without relationship to the duration of erytropoietin treatment. There was influence of hemoglobin level on the results of the test.
  
  
  CONCLUSIONS
  Results of the MTC test in end-stage renal disease patients is inadequate and the PRL response is diminished. Diagnostic value of the test in end-stage renal disease patients is low. Erytropoietin administration improves although not to the normal values the results of the MTC test.
authors.affiliation: Oddział Chorób Wewnetrznych ze Stacja Dializ SZP ZOZ Wołomin. nephro@amwaw.edu.pl
authors.forename: Stanisław
authors.initials: S
authors.lastname: Niemczyk
authors.forename: Joanna
authors.initials: J
authors.lastname: Matuszkiewicz-Rowńska
authors.forename: Katarzyna
authors.initials: K
authors.lastname: Szamotulska
authors.forename: Zofia
authors.initials: Z
authors.lastname: Sitkowska-Kurzec
authors.forename: Małgorzata
authors.initials: M
authors.lastname: Gomółka
authors.forename: Marek
authors.initials: M
authors.lastname: Stopiński
authors.forename: Janusz
authors.initials: J
authors.lastname: Grochowski
authors.forename: Longin
authors.initials: L
authors.lastname: Niemczyk
authors.forename: Grzegorz
authors.initials: G
authors.lastname: Ostrowski
authors.forename: Paweł
authors.initials: P
authors.lastname: Kulicki
mesh_terms: D000328:Adult; D000368:Aged; D016022:Case-Control Studies; D005260:Female; D006801:Humans; D006966:Hyperprolactinemia / Q000097:blood*; D007676:Kidney Failure, Chronic / Q000097:blood*; D008297:Male; D008787:Metoclopramide / Q000494:pharmacology*; D008875:Middle Aged; D010902:Pituitary Gland / Q000187:drug effects*; D011388:Prolactin / Q000097:blood*
chemical_list: D011388:Prolactin; D008787:Metoclopramide